Boehringer Ingelheim
The main objective of this trial is to investigate the induction effect of multiple doses of BI 1015550 on the pharmacokinetics of the sensitive CYP3A4 substrate midazolam.
Healthy
BI 1015550
midazolam
Phase 1
Study Type : | Interventional |
Estimated Enrollment : | 15 participants |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | The Effect of Multiple Oral Doses of BI 1015550 on Metabolism of Midazolam Administered Orally in Healthy Male Subjects (Open-label, Two-period Fixed Sequence Design Trial) |
Actual Study Start Date : | October 11, 2022 |
Estimated Primary Completion Date : | December 16, 2022 |
Estimated Study Completion Date : | December 16, 2022 |
Arm | Intervention/treatment |
---|---|
Experimental: BI 1015550 + midazolam treatment arm test and reference treatment arm |
Drug: BI 1015550 Drug: midazolam |
Ages Eligible for Study: | 18 Years to 55 Years |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | Accepts Healthy Volunteers |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
CRS Clinical Research Services Mannheim GmbH
Mannheim, Germany, 68167